The median net launch price of newly approved U.S. prescription drugs rose 35% after adjusting for inflation, increasing from $190,000 in 2022 to $257,000 in 2025, according to a report by ICER and West Health.

The psychological effect on a patient of receiving a drug prescribed by a doctor is beneficial in itself

552c7ae14Claim

President Donald Trump nominated wellness influencer Dr. Casey Means for surgeon general, but her nomination was withdrawn after Senate confirmation stalled over concerns regarding her medical experience and vaccine stances

552c7ae14Claim

In an October 22, 2026 statement announcing his resignation, Calley Means, a senior adviser to Health and Human Services Secretary Robert F. Kennedy Jr., expressed tremendous respect for President Donald Trump and Kennedy without stating a reason

552c7ae14Claim

Calley Means and his statement on October 22, 2026 highlighted Make America Healthy Again policy achievements, including expanding access to psychedelics, overhauling dietary guidelines, and limiting SNAP benefits for sugary drinks

552c7ae14Claim

While serving at the Department of Health and Human Services, Calley Means attacked leading physician groups, federal agencies, and government scientists, claiming they protect their own interests

552c7ae14Claim

The United States Medicaid program faces nearly $1 trillion in federal funding cuts over the coming decade

552c7ae14Claim

Approximately 25% of new prescription drugs launched in the U.S. in 2025 had annual net prices exceeding $500,000, while another 34% were priced between $200,000 and $500,000.

552c7ae14Claim

Donald Trump has formed more than a dozen deals asking drugmakers to adopt most-favored nation drug pricing in exchange for tariff relief.

552c7ae14Claim

The median list price for newly approved U.S. prescription drugs, adjusted for inflation, rose 24% from 2022 to $293,000 in 2025.

552c7ae14Claim

Two-thirds of newly approved prescription drugs reviewed by the Institute for Clinical and Economic Review between 2022 and 2025 were launched at prices exceeding ICER's cost-effectiveness thresholds.

552c7ae14Claim

Four in 10 prescription claims for the 26 new medicines reviewed by ICER between 2022 and 2025 were rejected by health insurers.

552c7ae14Claim

PhRMA spokesperson Chanse Jones acknowledged that coverage rejections and administrative hurdles by insurers delay and deny patient access to new treatments.

552c7ae14Claim

The Institute for Clinical and Economic Review suggested drug manufacturers may be raising launch prices to maximize profits before government Medicare price negotiations and most-favored nation pricing deals take effect.

552c7ae14Claim

An August 2026 draft report by ICER found that new aldosterone synthase inhibitor hypertension drugs cost between $833,000 and $2.08 million per quality-adjusted life year gained compared with generic alternatives.

552c7ae14Claim

Mineralys Therapeutics' aldosterone synthase inhibitor lorundrostat has an FDA action date scheduled for December 22, 2026.

552c7ae14Claim

The Institute for Clinical and Economic Review estimated that Insmed's lung-disease drug Brinsupri and Merck & Co.'s Winrevair require 90% price discounts to meet cost-effectiveness guidelines.

552c7ae14Claim

Nearly two-thirds of Medicare claims for 26 outpatient drugs analyzed by ICER were rejected within 30 days of initial submission due to coverage restrictions or pretreatment reviews.

552c7ae14Claim

AstraZeneca's baxdrostat was approved by the FDA in May 2026 for treatment-resistant hypertension following positive Phase 3 BaxHTN trial results.

552c7ae14Claim

An ICER equity analysis calculated that Black Americans, who have a 57.8% hypertension prevalence rate, could see 20% greater benefit from effective blood pressure treatments than the general U.S. population.

Doctors should be allowed to prescribe undisclosed placebos when no effective treatment exists

The psychological effect on a patient of receiving a drug prescribed by a doctor is beneficial in itself

President Donald Trump nominated wellness influencer Dr. Casey Means for surgeon general, but her nomination was withdrawn after Senate confirmation stalled over concerns regarding her medical experience and vaccine stances

In an October 22, 2026 statement announcing his resignation, Calley Means, a senior adviser to Health and Human Services Secretary Robert F. Kennedy Jr., expressed tremendous respect for President Donald Trump and Kennedy without stating a reason

Calley Means and his statement on October 22, 2026 highlighted Make America Healthy Again policy achievements, including expanding access to psychedelics, overhauling dietary guidelines, and limiting SNAP benefits for sugary drinks

While serving at the Department of Health and Human Services, Calley Means attacked leading physician groups, federal agencies, and government scientists, claiming they protect their own interests

The United States Medicaid program faces nearly $1 trillion in federal funding cuts over the coming decade

Approximately 25% of new prescription drugs launched in the U.S. in 2025 had annual net prices exceeding $500,000, while another 34% were priced between $200,000 and $500,000.

Donald Trump has formed more than a dozen deals asking drugmakers to adopt most-favored nation drug pricing in exchange for tariff relief.

The median list price for newly approved U.S. prescription drugs, adjusted for inflation, rose 24% from 2022 to $293,000 in 2025.

Two-thirds of newly approved prescription drugs reviewed by the Institute for Clinical and Economic Review between 2022 and 2025 were launched at prices exceeding ICER's cost-effectiveness thresholds.

Four in 10 prescription claims for the 26 new medicines reviewed by ICER between 2022 and 2025 were rejected by health insurers.

PhRMA spokesperson Chanse Jones acknowledged that coverage rejections and administrative hurdles by insurers delay and deny patient access to new treatments.

The Institute for Clinical and Economic Review suggested drug manufacturers may be raising launch prices to maximize profits before government Medicare price negotiations and most-favored nation pricing deals take effect.

An August 2026 draft report by ICER found that new aldosterone synthase inhibitor hypertension drugs cost between $833,000 and $2.08 million per quality-adjusted life year gained compared with generic alternatives.

Mineralys Therapeutics' aldosterone synthase inhibitor lorundrostat has an FDA action date scheduled for December 22, 2026.

The Institute for Clinical and Economic Review estimated that Insmed's lung-disease drug Brinsupri and Merck & Co.'s Winrevair require 90% price discounts to meet cost-effectiveness guidelines.

Nearly two-thirds of Medicare claims for 26 outpatient drugs analyzed by ICER were rejected within 30 days of initial submission due to coverage restrictions or pretreatment reviews.

AstraZeneca's baxdrostat was approved by the FDA in May 2026 for treatment-resistant hypertension following positive Phase 3 BaxHTN trial results.

An ICER equity analysis calculated that Black Americans, who have a 57.8% hypertension prevalence rate, could see 20% greater benefit from effective blood pressure treatments than the general U.S. population.